Ironvine Capital Partners LLC Reduces Position in Danaher Corporation $DHR

Key Points

• Ironvine Capital Partners LLC reduced its stake in Danaher Corporation by 16.6% in Q1, now holding 106,103 shares valued at approximately $21.75 million.
• A number of analysts have set new price targets for Danaher, with Royal Bank of Canada targeting $241.00 and Wells Fargo reducing their target from $210.00 to $205.00.
• Danaher reported quarterly earnings of $1.80 per share, exceeding analysts' expectations and indicating a 3.4% year-over-year revenue increase, with a guidance of 7.700-7.800 EPS for FY 2025.

Ironvine Capital Partners LLC reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 16.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 106,103 shares of the conglomerate's stock after selling 21,122 shares during the period. Danaher accounts for approximately 2.4% of Ironvine Capital Partners LLC's portfolio, making the stock its 18th largest holding. Ironvine Capital Partners LLC's holdings in Danaher were worth $21,751,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. Bank Pictet & Cie Europe AG increased its position in shares of Danaher by 22.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock valued at $44,241,000 after buying an additional 35,730 shares during the period. Cetera Investment Advisers increased its position in shares of Danaher by 0.9% during the fourth quarter. Cetera Investment Advisers now owns 134,273 shares of the conglomerate's stock valued at $30,822,000 after buying an additional 1,189 shares during the period. Colonial Trust Co SC increased its position in shares of Danaher by 288.6% during the fourth quarter. Colonial Trust Co SC now owns 4,628 shares of the conglomerate's stock valued at $1,062,000 after buying an additional 3,437 shares during the period. EP Wealth Advisors LLC increased its position in shares of Danaher by 0.8% during the fourth quarter. EP Wealth Advisors LLC now owns 27,275 shares of the conglomerate's stock valued at $6,261,000 after buying an additional 210 shares during the period. Finally, Coastal Bridge Advisors LLC increased its position in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after buying an additional 50 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DHR has been the topic of several analyst reports. Evercore ISI decreased their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Robert W. Baird boosted their price objective on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.20% of the company's stock.

Danaher Price Performance

DHR traded down $4.39 during midday trading on Tuesday, hitting $194.24. The stock had a trading volume of 3,344,662 shares, compared to its average volume of 4,138,020. The company has a market cap of $139.09 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 2.79 and a beta of 0.75. The business has a fifty day moving average of $201.95 and a 200 day moving average of $199.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.